Compounded semaglutide vs Ozempic: what is different?
Ozempic is one named product, approved by the FDA and in the EU, and the studies behind it tested Ozempic itself1,8. Compounded semaglutide is made by a pharmacy or an outsourcing facility, is not FDA approved, and gets no FDA check of its safety, effectiveness or quality before it is sold2,5,10.
| What to compare | Ozempic | Compounded semaglutide |
|---|---|---|
| Who makes it | Novo Nordisk1 | A state-licensed pharmacy or an outsourcing facility2 |
| Approved as this exact product? | Yes: FDA application NDA 209637, and an EU authorisation since 8 February 20181,8 | No. The FDA says compounded drugs are not FDA approved5 |
| What the studies tested | Ozempic itself. The EU summary reports five studies in over 4,000 patients1 | The FDA does not review compounded drugs for safety or effectiveness before they are sold5 |
| Active ingredient | Semaglutide8 | Sometimes semaglutide sodium or semaglutide acetate, which the FDA calls different active ingredients3 |
| Quality checked before sale? | Yes. The FDA's approval process verifies safety, effectiveness and quality10 | No. The FDA does not verify the quality of compounded drugs before they are marketed10 |
| What lets it be sold | Its approval1,8 | For copies of semaglutide, the shortage exception ended 22 April 2025 for pharmacies and 22 May 2025 for outsourcing facilities2 |
- Compounded semaglutide
- No. The FDA says compounded drugs are not FDA approved5
Holding a pen and not sure it is the real product? The Fake GLP-1 Check walks you through the label and the lot number.
Is semaglutide a peptide, and is it the same thing as Ozempic?
Semaglutide is a peptide, and it is not the same thing as Ozempic. Semaglutide is the molecule: a lab-made version of the gut hormone GLP-1 that shares 94% of its sequence with the human version, built on a peptide backbone made by yeast fermentation1,9. Ozempic is one product made from it by Novo Nordisk8.
So a label that says semaglutide names a molecule. It does not tell you who made the vial, or whether any regulator reviewed that product. The semaglutide record shows which products the approval studies tested.
Was compounded semaglutide ever legal, and is it now?
It was, under a temporary rule that has ended. Pharmacies may compound copies of a drug while it is in shortage, and the FDA declared the semaglutide injection shortage resolved as of 21 February 20252.
The FDA then gave compounders time to stop. That grace period ended on 22 April 2025 for state-licensed pharmacies and on 22 May 2025 for outsourcing facilities2. As of October 2026 both dates are long past, so the shortage rule that once let pharmacies copy semaglutide broadly no longer applies2.
Is compounded semaglutide the same ingredient as Ozempic?
Not always. The FDA says some compounders use semaglutide sodium or semaglutide acetate, and that these salt forms are different active ingredients than the ones in the approved drugs3.
The FDA also says it has no information on whether these salts have the same chemical and pharmacologic properties as the approved ingredient3. So the word semaglutide on a label does not prove that the molecule inside matches the one in an Ozempic pen.
What safety problems has the FDA linked to compounded semaglutide?
Dosing mistakes. In July 2024 the FDA warned that unfamiliarity with drawing the medicine from a vial into a syringe, and confusion between units of measure, may have contributed to dosing errors with compounded semaglutide4.
The FDA tied the problem to compounders offering several concentrations at once, syringes larger than the volume needed, and instructions written in units where patients expected milligrams or millilitres4. That risk exists even when a batch is pure and correctly labelled.
What happens when sellers sell semaglutide outside the rules?
The FDA treats it as selling an unapproved drug. Its August 2026 warning letter to an online peptide seller named semaglutide among the products cited as unapproved new drugs, despite the seller's 'research use only' and 'not for human consumption' labelling6.
The FDA also warns about improper storage during shipping, contamination in multi-dose vials used beyond 28 days, and counterfeit products sold under false pharmacy names5. The same question about tirzepatide has its own answer: Is compounded tirzepatide the same as Zepbound?
What did lab tests find in semaglutide sold online?
Every sample was judged probably substandard or falsified. A 2024 peer-reviewed study bought semaglutide from online sellers without a prescription and tested what arrived7.
Content ran 28.56 to 38.69 percent above the labelled amount, purity ran between 7.7 and 14.37 percent against a 99 percent claim, and endotoxin turned up in every sample7. The study bought from online sellers, not from licensed compounding pharmacies, so read it as a finding about the online market.
What would change this answer
An FDA reversal reinstating shortage status for semaglutide, a published FDA or peer-reviewed comparison of licensed-compounding-pharmacy semaglutide against Ozempic's approved specifications, or a new FDA safety communication specifically addressing salt-form pharmacology data, which FDA currently states it lacks, would each change parts of this answer.
Three questions to ask next
Has FDA published any data confirming or ruling out that semaglutide sodium or semaglutide acetate behave pharmacologically like the approved product's active ingredient?
Are any 503A or 503B compounding pathways still legally open for semaglutide today, given that the general shortage-based exception has expired, and if so under what narrower conditions?
Has an independent lab study tested semaglutide products specifically from licensed compounding pharmacies, rather than unregulated online sellers, for comparison against Ozempic's approved specifications?
Ask better questions.
- [1] Ozempic: EPAR, authorised 8 February 2018, Novo Nordisk A/S (opens in new tab). European Medicines AgencyBack to text (first mention of source 1)
- [2] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (opens in new tab). FDA, updated 1 April 2026Back to text (first mention of source 2)
- [3] FDA's concerns with unapproved GLP-1 drugs used for weight loss (salt-form active-ingredient status) (opens in new tab). FDA, content current as of 1 October 2026Back to text (first mention of source 3)
- [4] FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (opens in new tab). FDA, 26 July 2024Back to text (first mention of source 4)
- [5] Same FDA concerns page: no premarket review, storage and contamination risks (opens in new tab). FDA, content current as of 1 October 2026Back to text (first mention of source 5)
- [6] FDA warning letter to an online peptide seller naming semaglutide, 24 August 2026 (opens in new tab). FDA (CDER)Back to text (first mention of source 6)
- [7] Quality and safety analysis of semaglutide sold online without prescription (opens in new tab). J Med Internet Res 2024, PMID 39509151Back to text (first mention of source 7)
- [8] Drugs@FDA: NDA 209637, Ozempic (semaglutide) (opens in new tab). FDA, read 25 October 2026Back to text (first mention of source 8)
- [9] Ozempic prescribing information: description and mechanism of action (opens in new tab). DailyMed (NLM), label revised January 2026Back to text (first mention of source 9)
- [10] Compounding and the FDA: questions and answers (opens in new tab). FDA, content current as of 16 September 2025Back to text (first mention of source 10)